Please login to the form below
Cornerstone Therapeutics
This page shows the latest Cornerstone Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Chiesi hits the acquisition trail again
company Cornerstone Therapeutics. ... The value of the deal is around $107m and all in all values Cornerstone at some $255m.
Latest news
-
Biologics buoyant
Three of the deals, with Amplimmune, FivePrime Therapeutics and Genmab, focus on biologics. ... 84+. Cornerstone Therapeutics/Targacept . Alpha-7 and other nicotinic receptor targeting compounds. Preclinical .
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch table for September 2013
Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... Cornerstone Therapeutics, respectively.
Deal Watch table for September 2013
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital strategist
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
-
Digital project manager
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Straight outta lockdown – what’s next for flexible working?
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Onyx Health Launch Creative Studio After Record Year
- Straight outta lockdown – what’s next for flexible working?
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’
- Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
